CD Skripsi
Analisis Ekspresi Gen Muts Homolog 2 Pada Kanker Endometrium
Endometrial cancer is a malignancy originating from the epithelial lining of the uterus. Previous studies have reported that dysregulation of the DNA mismatch repair (MMR) system occurs in more than 30% of endometrial cancer cases, with Muts Homolog 2 (MSH2) gene become the MMR gene with the highest mutation rate. The high mutation frequency and the crucial role of the MSH2 gene in the early stages of DNA repair suggest its potential as a novel biomarker for early detection of endometrial cancer. This study aimed to determine the differences in MSH2 gene expression between normal endometrial tissue and endometrial cancer tissue, as well as to analyze its association with age,cancer stage, histological grade, histological type, molecular classification, and overall survival in endometrial cancer. Patient data were obtained from the TCGA, GDC, and cBioPortal datasets, using an analytical cross-sectional study design and a total sampling technique. The results showed that the majority of endometrial cancer patients were aged 61–70 years, with early-stage disease, high histological grade, histopathological type 1, and molecular classification of NSMP/cnl. In conclusion, the expression of the MSH2 gene was significantly higher in endometrial cancer tissues compared to normal endometrial tissues (p < 0.05) and also showed significant association with age(p < 0.05) , stage(p < 0.05), grade(p < 0.05), histological type(p < 0.05), molecular classification(p < 0.05) of endometrium cancer. Moreover, patients with low MSH2 gene expression (83%) demonstrated better overall survival compared to those with high MSH2 gene expression (71%).
Key Words: endometrial cancer, gene expression, MSH2 gene
Tidak tersedia versi lain